Interim Report 2018

PACIFIC EDGE LIMITED
INTERIM REPORT 2018
FOR THE SIX MONTHS
TO 30 SEPTEMBER 2018

PACIFIC EDGE LIMITED INTERIM REPORT 2018PACIFIC EDGE LIMITED INTERIM REPORT 2018
3 2
The Board of Directors of Pacific Edge Limited
is pleased to present the Interim Report for
the six months to 30 September 2018.
Chris Gallaher David Darling
Chairman Chief Executive
Cxbladder: Enabling Better Care 3
Year To Date Highlights 4
Contract Coverage 5
First Half Financial Performance 6
Financial Review 7
Chair and CEO Review 9
New Opportunities 12
Interim Financial Statements 14
Notes to the Financial Statements 20
Directory & Communications Back cover
CXBLADDER: ENABLING
BETTER CARE
Cxbladder is a world-leading molecular
diagnostic test for urothelial cancer.
1
It is
non-invasive and more accurate than other
tests, and provides a significant value
proposition for patients, physicians and
payees alike.
The suite of Cxbladder tests encompasses
many of the physician’s decision points
across the urothelial cancer pathway, from
investigation of haematuria (blood in the
urine and a key indicator of bladder cancer)
to detection and management of patients
for recurrence of the disease.
Our goal is to enable better patient care,
better clinical decision making and better
use of healthcare resources by providing
improved diagnosis and management of
bladder cancer.
The company is targeting large healthcare
organisations, particularly in the US
healthcare market which offers an estimated
annual market opportunity of US$1.2 billion
for Cxbladder.
In New Zealand, Cxbladder has already
achieved more than 60% market penetration
and is actively being used by the majority
of the large public healthcare providers,
replacing the gold standard, cystoscopy, in
some guidelines.
1
Urothelial cancer covers cancers of the urinary tract.
The majority are bladder cancer but also include
epithelial cancers of the upper tract.

PACIFIC EDGE LIMITED INTERIM REPORT 2018
5 4
YEAR TO DATE HIGHLIGHTS
• Continuing growth in product sales and adoption of Cxbladder by leading
healthcare organisations and urologists, in Pacific Edge’s targeted markets of
New Zealand, Australia, Singapore and the United States.
• Increased focus on institutional healthcare organisations in all markets is
providing commercial traction.
• High levels of commercial adoption of Cxbladder in Pacific Edge’s home market
of New Zealand. Total contract coverage of New Zealand’s population now
approximately 62%.
• Continuing commercial negotiations and start-up processes with targeted
institutional customers in the USA, including Kaiser Permanente.
• Completion of two of the three milestones required for US reimbursement, being
receipt of product codes and notification of a national price (US$760 per test).
• Progress continues to be made with the third of these cornerstones, which is to
have Cxbladder included in the Local Coverage Determination. This will allow for
reimbursement of tests used by patients covered by the CMS.
• Commencement of commercial evaluation with Johns Hopkins Medicine, a US$8
billion integrated global health enterprise and one of the leading health care
systems in the USA.
• User Programmes underway with five targeted hospitals in Singapore. Several are
nearing completion and the focus will shift to transitioning these to commercial
customers.
• Taken over the sales and distribution of Cxbladder in Australia, building on the
successful practices in the New Zealand market.
• Investment of $2.6m by US private investment fund, Manchester Management
Company, which specialises in biotech and life sciences investments.
• Completion of successful $7m placement, with a number of new local and
international institutional investors welcomed to the register.
• Announced $5m Share Purchase Plan at no greater than the placement price
($0.35 per share), which will close on 25 January 2019.

CONTRACT COVERAGE OF NEW ZEALAND’S POPULATION
USING CXBLADDER
NOVEMBER 2018
PACIFIC EDGE LIMITED INTERIM REPORT 2018
Approx. 62% of New Zealand’s
population - that’s over 2.9 million
people - have
access to Cxbladder
through their public healthcare providers

PACIFIC EDGE LIMITED INTERIM REPORT 2018
7 6
LABORATORY THROUGHPUT
Includes User Programmes and
commercial tests
Total laboratory throughput for
1H19: 7,397 tests, of which approx.
82% were billable
12% increase in billable tests,
consolidating and growing the
strong numbers in 1H18
■ 1H ■ 2H

0
2000
4000
6000
8000
10000
12000
14000
16000
FY15FY16FY17FY18FY19
NUMBER OF TESTS
FINANCIAL REVIEW
We were pleased to report the continuing uplift in our financial performance, as we continue to
invest into the growth of our business and drive commercial sales. Financial highlights include
a 43% increase in revenue from test sales, a 15% decrease in operating cash outflow and a 13%
improvement in the bottom line result.
LABORATORY THROUGHPUT
Adoption of Cxbladder is growing and commercial sales are increasing. Laboratory throughput,
which includes commercial sales and tests from User Programmes, was 7,397 tests. A growing
percentage of these tests are billable, up to 82% from 76% in 1H18.
OPERATING REVENUE
Operating revenue
2
from test sales was up 43% to $2.0m, with total revenue for the period of
$2.6m. The company accounts for its US revenue on a cash basis, and therefore reported revenue
excludes tests sold in the USA for which cash payment has yet to be received, as well as tests
completed for patients covered by the Centers for Medicare and Medicaid Services (CMS).
3

The average payment received per test by Pacific Edge is dependent on the mix of payers and
insurance plans of each patient and can vary significantly from period to period.
INVESTMENT INTO GROWTH
While we are a young and fast growing medical technology company in the early stages of our
commercial journey, we have a prudent approach to our investment into growth. Pleasingly,
operating expenses for the half year were down 6% to $11.4m with revenue outgrowing expenses
by a net 13%. Operating expenses include research and development costs of $1.7m (a 23% year
on year decrease), with the remainder being direct operating costs.
NET OPERATING CASHFLOWS
Net operating cashflow improved to $(8.6)m for the period, a 15% improvement on the previous
first half year. Cash receipts from customers increased by 22% to $2.0m, with a large portion of the
cash received in 1H19 being for tests sold in prior years.
REDUCED NET LOSS
Overall, the Company reported a net loss of $(8.7)m for the half year, an improvement of 13% on
the prior first half year loss of $(10.0)m.
FUNDING AND CAPITAL MANAGEMENT
Pacific Edge had $10.1m in cash, cash equivalents and short term deposits at 30 September 2018
which includes the investment of approximately $2.6m by US private investment fund, Manchester
Management Company, which specialises in biotech and life sciences investments. We are
undertaking a $12m capital raise, by way of a private placement and share purchase plan, to assist
in progressing our commercial objectives and becoming cash flow positive as soon as possible. A
number of new and local institutional investors joined the register through the placement and the
Pacific Edge’s bankers receipted their fees in equity.
2
Pacific Edge adopted NZ IFRS 15 in FY18. This means revenue for US based customers is now only recognised when the cash is received.
Under the previous accounting standard, which took into account all tests sold but which may not have yet been paid for, operating revenue
would have been $5.6m in 1H19, compared to $4.2m in 1H18 (an increase of 33%).
3
CMS tests account for approximately 47% of annual US laboratory throughput and cumulatively totalled in excess of 14,000 tests as at
30 September 2018. Pacific Edge will seek reimbursement for these when it is included in the CMS’s Local Coverage Determination (LCD).
Until then, these tests remain in the billing and reimbursement process and revenue will be accounted for when the cash is received.
PACIFIC EDGE LIMITED INTERIM REPORT 2018
FY19 FIRST HALF YEAR FINANCIAL PERFORMANCE
POSITIVE UPLIFT ON PRIOR FIRST HALF YEAR:
43%
29%
13%
13%
6%
15%
INCREASE IN REVENUE FROM
TEST SALES TO $2.0M
INCREASE IN TOTAL REVENUE

TO $2.6M
IMPROVEMENT IN NET LOSS

TO $(8.7)M
REDUCTION IN TOTAL OPERATING
EXPENSES TO $(11.4)M
IMPROVEMENT IN NET OPERATING
CASH OUTFLOW TO $(8.6)M
CASH, CASH EQUIVALENTS AND
SHORT TERM DEPOSITS $10.1M

AS AT 30 SEPTEMBER 2018
REVENUE OUTGROWING
EXPENSES BY A NET 13%

PACIFIC EDGE LIMITED INTERIM REPORT 2018
9 8
CHAIR AND CEO REVIEW
The Board and management of Pacific Edge continue to work hard to progress our
commercial journey in the USA. While this is taking longer than initially anticipated,
progress has been made in the 2019 financial year to date with several notable
highlights.
The first was the adoption of Cxbladder into the clinical guidelines for several of the
public healthcare providers in New Zealand, and the consequential replacement of the
gold standard, cystoscopy.
The second was the notification of the national test price for the Centers for Medicare
and Medicaid (CMS) of US$760 per test, completing two of the three reimbursement
milestones in the US. The combination of both the national price and the product
specific code will enable the start of negotiations with private payers (insurance
companies).
The third has been the engagement with a number of large healthcare organisations in
the US, which led to the commencement of a commercial evaluation with Johns Hopkins
Medicine. This is an $8 billion integrated global health enterprise and one of the leading
healthcare systems in the United States.
THE US MARKET REMAINS OUR PRIORITY
The USA market has an identified US$1.2 billion addressable annual market for
our Cxbladder bladder cancer diagnostic test
4
. We remain focused on completing
agreements and building sales from the large institutional accounts and payers we are
targeting, including Johns Hopkins Medicine (recently announced), Kaiser Permanente,
the Veterans Administration and Tricare, the CMS and other blue chip institutions.
We have now completed two of the three cornerstones of the USA national
reimbursement process, and progress continues to be made with the third of these
cornerstones, which is to have Cxbladder included in the Local Coverage Determination.
This will allow for reimbursement of tests used by patients covered by the CMS.
The process is largely driven by peer-reviewed, published clinical and utility evidence for
the Cxbladder products, with a general ‘rule of thumb’ being that it takes around five
years to generate the specific evidence and gain inclusion into the LCD. We commenced
the LCD process in 2014 and continue to make good progress.
VALIDATION FROM NZ PUBLIC HEALTHCARE PROVIDERS AT VERY HIGH LEVELS
New Zealand’s public healthcare providers continue to lead the way with some significant
global firsts. The majority of New Zealand’s public healthcare providers have now adopted
Cxbladder into their standard of care and, in some cases, their clinical guidelines,
replacing the gold standard, cystoscopy.
4
EY Parthenon review of Cxbladder market size in the USA. Company strategy review document.
PACIFIC EDGE LIMITED INTERIM REPORT 2018

essential part of the Local Coverage Determination (LCD) evaluation process that we have underway
in the USA, for CMS patients.
OUTLOOK
Successful commercialistation of medical devices is a long process involving significant resources of
time and investment into the development of the clinical evidence to support the reimbursement.
Many of the foundations for commercial success have now been completed. There is no longer
any question of Cxbladder’s clinical performance and the real difference it is making for physicians,
patients and payees alike. We are seeing growing adoption of Cxbladder in all markets and the
progressive translation into sales growth.
In line with annual trends, we are expecting a stronger second half year as Americans with private
healthcare insurance reach their annual fixed deductible level (the amount a patient must pay
before their insurance cover commences) and they start to undertake the medically recommended
actions and treatments for which they will be reimbursed by their insurance company.
We also expect to see demand from public healthcare providers in New Zealand positively impact
commercial test throughput volumes in the second half of FY19.
Laboratory throughput is expected to increase by approximately 20% in the second half of FY19,
taking laboratory throughput for the full year to approximately 16,000 to 17,000 tests (FY18: 14,448
tests). Approximately 82% of these tests are expected to be billable, equating to a 14% year-on-
year increase in commercial test volumes.
The expected laboratory throughput in FY19 excludes test volumes from any new commercial
agreements which have yet to be signed. The New Zealand market is expected to make a growing
contribution to total laboratory throughput in FY19.
We remain focused on completing the national US reimbursement process for CMS patients,
with the final step being inclusion in the Local Coverage Determination, which will allow us to be
reimbursed for tests used by patients covered by the CMS.
Forward growth in commercial tests in the US will benefit from having national product specific
codes for Cxbladder and a national CMS reimbursement price. These milestones enable us to move
into the process of negotiating contract terms with private payers, which will enable a shortening of
the overall commercial transaction time and a positive reduction in the time to receipt of cash.
We now have a proven business model, as can be seen in the uptake of Cxbladder in New Zealand,
and we will use learnings from this to replicate our success in other international markets. We
are prudently managing our costs and capital expenditure and are focused on gaining adoption
from the large healthcare organisations which will be drivers of success in our business. While our
original growth expectations have been impacted by the longer than expected time to conclude
commercial arrangements with two large US customers, we are making good progress with other
key milestone achievements.
We remain committed to the company’s strategy. Hard won experience tells us that everything in
the USA market takes longer than we planned, however good progress has been made in the half
year, and we remain focused on achieving our key milestone of cashflow breakeven as we take
Cxbladder to the world.
Chris Gallaher David Darling
Chairman Chief Executive Officer
Timely, accurate diagnosis, ease of use and rapid turnaround are important considerations in urologic
health and are the hallmarks of Cxbladder.
By including Cxbladder within the urology workup in regional settings such as New Zealand’s East
Coast, many patients can get the peace of mind that they don’t have bladder cancer from our easy-
to-use urine test, thereby avoiding a cystoscopy and the need to travel long distances to the hospital.
The commercial use of Cxbladder by New Zealand public healthcare providers has been shown
to reduce the number of unnecessary invasive tests and reduce lengthy waiting times for patients
referred for investigation of haematuria and can have a significant impact on the timeliness and
quality of care for urology patients.
Cxbladder’s total contract coverage of New Zealand’s population is now approximately 62%
and the remaining public healthcare providers are expected to follow suit. We expect to see the
contribution from New Zealand’s public healthcare providers continue to contribute to commercial
test throughput growth in the second half of FY19.
OTHER MARKETS
We are also making good progress in Singapore, which provides us with a stepping stone into South
East Asia with an estimated 1.8 million Cxbladder test opportunities per year in the region. User
Programmes are now underway in five hospitals we have targeted. Several are nearing completion
and we are focused on transitioning these to commercial customers as quickly as possible.
In Australia, we have recently taken over the sales and distribution of Cxbladder, building on the
sales and marketing practices we have successfully utilised in the New Zealand market.
INCREASED FOCUS ON LARGE HEALTHCARE ORGANISATIONS
Following the success in New Zealand with the increased uptake by the national public healthcare
providers, we have increased our focus on large institutional healthcare organisations in our USA,
South East Asia and Australasian markets. The impact Cxbladder makes for the large healthcare
providers who have burgeoning patient needs, few resources and need to show value changes for
their clinical services, is very clear.
While these customers can take longer to bring to completion, once commercial agreement is
reached, they can provide significant volume, require lower sales maintenance and deliver more
sustainable, longer term growth opportunities.
The recently announced commercial evaluation by Johns Hopkins Medicine is an example of this
in action. An initial group of urologists are using Cxbladder for patients requiring investigation of
haematuria (blood in the urine) for the presence of bladder cancer. Payment will be received by
Pacific Edge for these tests.
This commercial evaluation will allow Johns Hopkins’ urologists to evaluate and determine the best
fit for Cxbladder within their clinical practice and provide data specific to their organisation and
patients. It is a significant achievement for a small company like Pacific Edge to gain access to world
leading organisations such as this.
GROWING CLINICAL VALIDATION
We have a growing library of clinical studies and papers which builds the clinical evidence and
demonstrates the outperformance of our product compared to other commonly used tests and
procedures in use today. These are important for our discussions with healthcare organisations
and reimbursement entities seeking validation of the clinical utility of our product, and are also an
PACIFIC EDGE LIMITED INTERIM REPORT 2018
11 10
PACIFIC EDGE LIMITED INTERIM REPORT 2018

PACIFIC EDGE LIMITED INTERIM REPORT 2018
13 12
NEW OPPORTUNITIES IN THE CHANGING
HEALTHCARE MARKET
We are constantly monitoring trends in healthcare and the
opportunities these offer for our company. New legislation in the USA
is coming to bear this year with the implementation of the Medicare
Access and CHIP Reauthorization (MACRA) Act of 2015. This new
legislation will see physicians move from a fee-for-service model to
a value based healthcare offering. The Act requires physicians to
outline value-based solutions to be implemented in their business. For
urologists, one of the very few value-based solutions available to them
would be Cxbladder.
Technology is changing ‘how and where’ healthcare is delivered and
some of the big trends are ‘virtual medical care’ and ‘Doctor to your
house in an hour’.
In the future, many doctor-patient contacts will be online and
healthcare will be delivered to the patient in their home. This will
help to reduce costs and will free up limited resources for specialist,
trauma and emergency situations. Cxbladder is ideally suited to this
environment due to its multiple integrated products, ease of use,
ability to transport across international borders and a fast laboratory
turn-around time.
We also expect to see more large corporates follow in the footsteps
of Amazon, Berkshire Hathaway and JPMorgan Chase, as well as
ComCast, which are developing their own solutions for employee
healthcare, whether this be forming their own healthcare companies
and employee plans, using technology and apps to access healthcare
services or co-operating more closely with existing insurers to get the
best provision for their employees.
These new channels are disrupting the more traditional sales model in
the USA. We are watching closely and have the ability to quickly adapt
our sales strategy and redirect our specialised sales force, as and when
required.
PACIFIC EDGE LIMITED INTERIM REPORT 2018

INTERIM FINANCIAL
STATEMENTS
FOR THE SIX MONTHS
TO 30 SEPTEMBER 2018
15 14
Note: These Statements are to be read in conjunction with the Notes to the Financial Statements.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2018
STATEMENT OF COMPREHENSIVE INCOME
NOTES
UNAUDITED
SEPT 2018
6 MONTHS
($000)
UNAUDITED
SEPT 2017
6 MONTHS
($000)
RESTATED
AUDITED
MARCH 2018
12 MONTHS
($000)
REVENUE
Operating Revenue 5 2,033 1,425 3,400
Total Operating Revenue 2,033 1,425 3,400
Other Income5 442 538 1,242
Interest Income 169 81 231
Foreign Exchange (Loss)/Gain (5) 8 129
Total Revenue and Other Income 2,639 2,052 5,002
OPERATING EXPENSES
Laboratory Operations 2,356 2,289 4,619
Research 1,666 2,156 4,384
Sales and Marketing 4,434 4,401 9,436
General & Administration 2,902 3,245 6,207
Total Operating Expenses6 11,358 12,091 24,646
NET (LOSS) BEFORE TAX (8,719) (10,039) (19,644)
Income Tax Expense- - -
(LOSS) FOR THE YEAR AFTER TAX (8,719) (10,039) (19,644)
Translation of Foreign Operations 1 (26) (83)
TOTAL COMPREHENSIVE (LOSS) atttributable
to equity holders of the Company
(8,718) (10,065) (19,727)
Earnings per share for (loss) attributable to the
equity holders of the Company during the year
Basic and Diluted Earnings per share (0.019) (0.024) (0.045)
PACIFIC EDGE LIMITED INTERIM REPORT 2018

PACIFIC EDGE LIMITED INTERIM REPORT 2018
17 16
PACIFIC EDGE LIMITED INTERIM REPORT 2018
Note: These Statements are to be read in conjunction with the Notes to the Financial Statements.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2018
STATEMENT OF CHANGES IN EQUITY
NOTES
SHARE
CAPITAL
RETAINED
EARNINGS
SHARE BASED
PAYMENTS
RESERVE
FOREIGN CURRENCY
TRANSLATION
RESERVE
TOTAL
EQUITY
($000)($000)
RESTATED
($000)($000)
RESTATED
($000)
RESTATED
UNAUDITED 6 MONTHS TO SEPT 2017
Balance as at 31 March 2017
111,596 (94,507) 2,889 851 20,829
Adjustment on adoption of NZ IFRS 15 (net of tax)4- (5,968)- 112 (5,856)
Restated Balance as at 31 March 20174 111,596 (100,475) 2,889 963 14,973
Loss After Tax (as restated)- (10,039)- - (10,039)
Other Comprehensive Income (as restated)- - - (26) (26)
TOTAL COMPREHENSIVE (LOSS) atttributable to equity holders of the Company- (10,039)- (26) (10,065)
Transactions with owners in their capacity as owners:
Issue of Share Capital (net of expenses)- - ---
Exercise of Employee Share Options 112 - (18)- 94
Share Based Payments-Employee Remuneration 80 - -- 80
Share Based Payment-Employee Share Options- - 140 - 140
Balance as at 30 September 2017 111,788 (110,515) 3,011 937 5,222
AUDITED 12 MONTHS TO 31 MARCH 2018
Balance as at 31 March 2017 111,596 (100,475) 2,889 963 14,973
Loss after tax- (19,644)-- (19,644)
Other Comprehensive Income- - - (83) (83)
TOTAL COMPREHENSIVE (LOSS) atttributable to equity holders of the Company- (19,644)- (83) (19,727)
Transations with owners in their capacity as owners:
Issue of Share Capital (net of expenses)8 20,020 - -- 20,020
Exercise of Employee Share Options 112 - (18)- 94
Share Based Payments-Employee Remuneration 96 - -- 96
Share Based Payment-Employee Share Options- - 1,184 - 1,184
Balance as at 31 March 2018 131,824 (120,119) 4,055 880 16,640
UNAUDITED 6 MONTHS TO SEPT 2018
Balance as at 31 March 2018 131,824 (120,119) 4,055 880 16,640
Loss after tax- (8,719)-- (8,719)
Other Comprehensive Income- - - 1 1
TOTAL COMPREHENSIVE (LOSS) atttributable to equity holders of the Company- (8,719)- 1 (8,718)
Transations with owners in their capacity as owners:
Issue of Share Capital (net of expenses)8 2,600 - -- 2,600
Share Based Payment-Employee Remuneration88 - -- 88
Share Based Payment-Employee Share Options- - 284 - 284
Balance as at 30 September 2018 134,512 (128,838) 4,339 881 10,894

PACIFIC EDGE LIMITED INTERIM REPORT 2018
19 18
PACIFIC EDGE LIMITED INTERIM REPORT 2018
Note: These Statements are to be read in conjunction with the Notes to the Financial Statements.
For and on behalf of the Board of DirectorsDirector Director
Dated 29th day of November 2018
AS AT 30 SEPTEMBER 2018
BALANCE SHEET
NOTES
UNAUDITED
SEPT 2018
6 MONTHS
UNAUDITED
SEPT 2017
6 MONTHS
AUDITED
MARCH 2018
12 MONTHS
($000)($000)
RESTATED
($000)
CURRENT ASSETS
Cash and Cash Equivalents 4,560 3,997 5,242
Short Term Deposits 5,500 - 11,000
Receivables 836 991 1,064
Inventory 846 1,014 752
Other Assets 912 643 472
Total Current Assets 12,654 6,645 18,530
NON-CURRENT ASSETS
Property, Plant & Equipment 876 942 854
Intangible Assets 273 346 281
Total Non-Current Assets 1,149 1,288 1,135
TOTAL ASSETS 13,803 7,933 19,665
CURRENT LIABILITIES
Payables and Accruals 2,771 2,589 2,926
Finance Leases 90 69 73
Total Current Liabilities 2,861 2,658 2,999
NON-CURRENT LIABILITIES
Finance Leases 48 54 26
Total Non-Current Liabilities 48 54 26
TOTAL LIABILITIES 2,909 2,712 3,025
NET ASSETS 10,894 5,221 16,640
Represented by:
EQUITY
Share Capital8 134,512 111,788 131,824
Accumulated Losses (128,838) (110,515) (120,119)
Share Based Payments Reserve 4,339 3,011 4,055
Foreign Translation Reserve 881 937 880
TOTAL EQUITY 10,894 5,221 16,640
FURTHER INFORMATION:
Return on Assets (%)(63%)(127%)(100%)
Return on Equity (%)(80%)(192%)(119%)
Debt to Equity Ratio (%)27%52%18%
Net Tangible Assets Per Share ($) 0.022 0.012 0.035
Note: These Statements are to be read in conjunction with the Notes to the Financial Statements.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2018
STATEMENT OF CASH FLOWS
NOTES
UNAUDITED
SEPT 2018
6 MONTHS
UNAUDITED
SEPT 2017
6 MONTHS
AUDITED
MARCH 2018
12 MONTHS
($000)($000)($000)
CASH FLOWS TO OPERATING
ACTIVITIES
Cash was provided from:
Receipts from Customers 2,026 1,655 3,420
Receipts from Grant Providers 663 225 944
Interest Received 250 82 115
2,939 1,962 4,479
Cash was disbursed to:
Payments to Suppliers & Employees 11,610 12,101 22,575
Net GST change (59) 46 4
11,551 12,147 22,579
Net Cash Flows To Operating Activities9 (8,612) (10,185) (18,100)
CASH FLOWS FROM INVESTING
ACTIVITIES:
Cash was provided from:
Proceeds from Short Term Deposits 5,500 8,000 8,000
5,500 8,000 8,000
Cash was disbursed to:
Purchase of Short Term Deposits - - 11,000
Capital Expenditure on Plant and
Equipment
19 153 195
Capital Expenditure on Intangible Assets 71 106 140
90 259 11,335
Net Cash Flows From Investing Activities 5,410 7,741 (3,335)
CASH FLOWS FROM FINANCING
ACTIVITIES:
Cash was received from:
Ordinary Shares Issued 2,623 94 21,414
2,623 94 21,414
Cash was disbursed to:
Repayment of Finance Leases 43 17 59
Issue Expenses 23 - 1,298
66 17 1,357
Net Cash Flows From Financing Activities 2,557 77 20,057
Net (Decrease) in Cash Held (645) (2,367) (1,378)
Add Opening Cash Brought Forward 5,242 6,564 6,564
Effect of Exchange Rate Changes on Net
Cash
(37) (200) 56
Ending Cash Carried Forward 4,560 3,997 5,242

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2018
NOTES TO THE FINANCIAL STATEMENTS
1 . SUMMARY OF ACCOUNTING POLICIES
The unaudited interim financial statements (“Interim Financial Statements”) presented
are those of Pacific Edge Limited (“the Company”) and its subsidiaries (“the Group”).
The Company is registered and domiciled in New Zealand for the purpose of developing
and commercialising new diagnostic and prognostic tools for the early detection and
management of cancers. Pacific Edge Diagnostics New Zealand Limited and Pacific Edge
Diagnostics USA Limited are sales and marketing entities which also manage and operate
the laboratories used for the detection of bladder cancer. Pacific Edge Pty Limited’s
purpose is to research and develop the Cxbladder product and other prognostic tools.
Pacific Edge Diagnostics Singapore Pte Limited is a sales and marketing entity and Pacific
Edge Analytical Services Limited is a dormant entity.
The Company is a for-profit entity for the purposes of complying with Generally Accepted
Accounting Practices, registered in New Zealand under the Companies Act 1993 and is a
reporting entity for the purposes of the Financial Markets Conduct Act 2013. The Company
is listed with NZX Limited with its ordinary shares quoted on the NZX Main Board.
(a) Basis of Preparation of Financial Statements
The Interim Financial Statements for the six months ended 30 September 2018 have been
prepared in accordance with the requirements of the NZX Main Board Listing Rules.
The Interim Financial Statements have been prepared in accordance with NZ IAS 34 - Interim
Financial Reporting. In complying with NZ IAS 34, these consolidated Interim Financial
Statements also comply with IAS 34 - Interim Financial Reporting and should be read in
conjunction with the Company’s 2018 Annual Report.
The Interim Financial Statements are prepared on the basis of historical cost, except where
otherwise identified. The presentation currency used in the preparation of the financial
statements is New Zealand dollars and all values are rounded to the nearest thousand
dollars ($000).
(b) Accounting Policies
The Group has adopted NZ IFRS 9 Financial Instruments in the 2019 financial year. This has
not had a material impact on the financial statements.
All other accounting policies have been applied on a basis consistent with those used in the
audited financial statements of Pacific Edge Limited for the year ended 31 March 2018.
(c) Restatement of Comparatives
The Group made the decision to adopt NZ IFRS 15 (Revenue from Contracts with Customers)
at the end of the 2018 financial year. This has impacted previously reported revenue and
receivables balances and resulted in a restatement of comparatives in these interim financial
statements. Please refer to note 4 for further details or note 2 in the 2018 Annual Financial
Statements.
(d) Authorisation
The Interim Financial Statements were authorised by the Board of Directors on 29 November
2018.
(e) Audit
The Interim Financial Statements for 2017 and 2018 have not been audited. The comparative
full year financial results for the year ended 31 March 2018 have been audited.
(f) Basis of Consolidation
The following entities and the basis of their inclusion for consolidation in these Interim
Financial Statements are as follows:
Ownership Interests
& Voting Rights
Name of Subsidiary
Place of
Incorporation
(or registration)
and Operation
Principal Activity
30 Sept
2018
(%)
30 Sept
2017
(%)
Pacific Edge Diagnostics
New Zealand Limited
New Zealand
Sales, Marketing,
Commercial Laboratory
100100
Pacific Edge Pty LimitedAustralia
Biotechnology Research
& Development
100100
Pacific Edge Diagnostics
USA Limited
USA
Sales, Marketing,
Commercial Laboratory
100100
Pacific Edge Analytical
Services Limited
New ZealandDormant Company100100
Pacific Edge Diagnostics
Singapore Pte Limited
SingaporeSales & Marketing100100
2. INVESTMENT AND ADVANCES IN SUBSIDIARIES
The Interim Financial Statements incorporate the assets and liabilities and results of Pacific
Edge Diagnostics New Zealand Limited, Pacific Edge Diagnostics USA Limited, Pacific Edge
Diagnostics Singapore Pte Limited, Pacific Edge Analytical Services Limited and Pacific
Edge Pty Limited, all of which are 100% owned by the Company. Subsidiaries have a 31
March balance date. The investments in and advances to subsidiaries are eliminated on
consolidation in the Group financial statements.
3. DIVIDENDS
The Company does not propose to pay dividends to shareholders similar to previous years.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2018
NOTES TO THE FINANCIAL STATEMENTS
PACIFIC EDGE LIMITED INTERIM REPORT 2018
21 20
PACIFIC EDGE LIMITED INTERIM REPORT 2018

4. RESTATEMENT
NZ IFRS 15: Revenue from contracts with customers (NZ IFRS 15)
The Group previously reported in the Financial Statements for the year ended 31 March
2018 it had early adopted NZ IFRS 15 from 1 April 2017 which resulted in changes in
accounting policies and adjustments to the amounts recognised in the financial statements.
In accordance with the transition provisions in NZ IFRS 15, the Group adopted the new
rules retrospectively and has restated comparatives for the 2017 financial year. None of the
available practical expedients have been applied.
Following its initial assessment of NZ IFRS 15 in 2017, the Group previously indicated that
there would not be a significant impact on the financial statements from the adoption of
this standard. This assessment was based on the expected completion of large customer
agreements during FY18, in particular inclusion in the Local Coverage Determination (LCD)
with the Centers for Medicare and Medicaid (CMS) and signing a commercial contract with
Kaiser Permanente. As these agreements were not concluded during FY18, the Group
reassessed the impact of NZ IFRS 15 and decided that the adoption of this standard
would have a significant impact on the recognition of revenue relating to Cxbladder tests
undertaken for US customers. There is no material impact for contracts with customers not
based in the US.
The Group presented the FY18 Interim Financial Statements on the basis it was not intending
to adopt NZ IFRS 15 from 1 April 2017. Due to this significant impact on the Group’s reported
financial results, the Group subsequently decided it was appropriate to early adopt NZ IFRS
15. An explanation of the change in revenue recognition can be found in Note 2 of the
2018 Annual Financial Statements. The tables below outline the changes required to the
previously reported comparative Interim Financial Statements from 30 September 2017.
Impact of NZ IFRS 15 on Previously Reported Financial Results
The specific financial statement line items affected by the change to the accounting policy
for revenue recognition are shown below. The 31 March 2017 balance sheet adjustments
were disclosed in the 31 March 2018 financial statements. These have been included again
here for transparency of movements.
Opening Balance Sheet
31 March 2017
2017
Previously
Reported
AdjustmentTransition
Adjustment
2017
($000)($000)
(i)
($000)($000)
RESTATED
Balance Sheet
Accounts Receivable 6,519 (290) (5,566) 663 a
Total Current Assets 22,397 (290) (5,566) 16,541 a
Total Assets 23,563 (290) (5,566) 17,707 a
Net Assets 20,829 (290) (5,566) 14,973 a
Accumulated Losses (94,507) (284) (5,684) (100,475)c
Foreign Translation Reserve 851 6 106 963 b
Total Equity 20,829 (290) (5,566) 14,973 a
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2018
NOTES TO THE FINANCIAL STATEMENTS
(i) This adjustment represents the correction of the FY15 incorrect application of the accounting policy and the
restated foreign currency impact.
a) The transition adjustments reduce accounts receivable at 31 March 2017 to remove all previously
recognised Cxbladder tests trade receivables from the period that cannot be recognised under NZ IFRS 15.
b) Represents the foreign currency translation adjustment relating to adjustments a) above.
c) Reflects the net of adjustments a) and b) above.
Statement of Comprehensive Income for the six months ended 30 September 2017
The specific financial statement line items affected by the change to the accounting policy
for revenue recognition are as follows:
For the 6 months ended
30 September 2017
2017
Previously
Reported
AdjustmentTransition
Adjustment
2017
($000)($000)
(ii)
($000)($000)
RESTATED
Operating Revenue 4,225 - (2,800) 1,425 a
Total Operating Revenue 4,225 - (2,800) 1,425 a
Total Revenue 4,852 - (2,800) 2,052 a
General & Administration 4,671 - (1,426) 3,245 b
- Bad Debts 674 (277) (397) - b
- Doubtful Debts 752 - (752) - b
Total Operating Expenses 13,517 (277) (1,149) 12,091 b
Net Loss Before Tax (8,665) (277) (1,097) (10,039)c
Loss for the year after Tax (8,665) (277) (1,097) (10,039)c
Translation of Foreign
Operations
(220) 4 190 (26)d
Total Comprehensive Loss (8,885) (273) (907) (10,065)e
Basic and Diluted Earnings per
Share ($)
(0.022) (0.000) (0.002) (0.024)e
(ii) This adjustment represents the correction of the previously recognised FY15 revenue that was written off in FY17
including the related foreign currency impact.
a) US Cxbladder test revenue has reduced with the change in policy to a cash receipts basis.
b) The bad and doubtful debts expense recognised for trade receivables relating to US Cxbladder tests has
been reversed.
c) Reflects the net of adjustments a) and b) above.
d) Represents the foreign currency translation adjustment relating to adjustments a) and b) above.
e) The adjustment to total comprehensive loss and included in the calculation for basic and diluted earnings
per share is the net of adjustments c) and d) above.


FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2018
NOTES TO THE FINANCIAL STATEMENTS
PACIFIC EDGE LIMITED INTERIM REPORT 2018
23 22
PACIFIC EDGE LIMITED INTERIM REPORT 2018

Reclassification of Expenditure
Expenses within the Statement of Comprehensive Income have been reclassified from the
previously reported Interim Financial Statements for the six months ended 30 September
2017. The expenses from the six months ended 30 September 2018 have been prepared on
this new basis. The expenses for the year ended 31 March 2018 are consistent with what
was previously reported in the 31 March 2018 financial statements. The reclassification has
been made to better represent the nature of the costs as the business evolves to allow for
improved comparability.
These reclassifications do not change the total expenses recognised for the six months
ended 30 September 2017. However, total expenses for the 2017 half year have changed
as a result of the implementation of NZ IFRS 15, which is further explained in Note 4 above.
The following reclassifications have been made for the six months ended 30 September 2017:
• Employee benefits, including salaries, wages, superannuation and health and disability
plans, previously included in other expenditure and totalling $3,262,000, have been re-
allocated to the functional areas as follows:
• Laboratory Operations: $700,000
• Sales and Marketing: $2,562,000
• Overhead expenditure, previously included in Other Expenses, totalling $2,195,000 has
been re-allocated to the functional areas as follows:
• Laboratory Operations: $971,000
• Research: $397,000
• Sales and Marketing: $827,000
5. REVENUE
Unaudited
Sept 2018
6 Months
($000)
Unaudited
Sept 2017
6 Months
($000)
Audited
March 2018
12 Months
($000)
Cxbladder Sales
- US1,8371,2743,188
- Rest of World196151212
Total Operating Revenue 2,0331,4253,400
Other Income
Grant Income352417853
Research Rebate Received90121389
Total Other Income4425381,242
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2018
NOTES TO THE FINANCIAL STATEMENTS
6. OPERATING EXPENSES
Unaudited
Sept 2018
6 Months
($000)
Unaudited
Sept 2017
6 Months
($000)
RESTATED
Audited
March 2018
12 Months
($000)
Operating Expenses
Amortisation 79 90 188
Auditors Remuneration - Audit Fees 118 56 89
- Other Assurance Services (refer below) 3 9 26
Depreciation 116 179 316
Directors Fees 136 137 275
Employee Benefits 5,184 5,773 11,129
Employee Share Scheme Expenses 88 80 96
Employee Share Options 284 141 1,184
Rental and Lease Expense 594 544 1,136
Other Operating Expenses 4,756 5,082 10,207
Total Operating Expenses 11,358 12,091 24,646
Other Assurance Services
Other assurance services performed by the auditor includes; agreed upon procedures,
review procedures and a review of the Callaghan Innovation Growth Grant claim.
Employee Share Scheme Expenses
Employee Share Scheme Expenses are a non-cash expense. These relate to shares issued to
employees in lieu of cash bonuses.
Employee Share Options
Employee Share Options are a non-cash expense. Refer to Note 10 of the annual report for
details of the accounting policy for Employee Share Schemes.
Other Operating Expenses
The major categories of expenditure which make up operating expenses, but are not disclosed
separately above include Laboratory costs, Information Technology costs, Compliance
and Regulatory costs, NZX and Registry fees, Investor Relations costs, Consultants and
Contractors.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2018
NOTES TO THE FINANCIAL STATEMENTS
PACIFIC EDGE LIMITED INTERIM REPORT 2018
25 24
PACIFIC EDGE LIMITED INTERIM REPORT 2018

7. SEGMENT INFORMATION
Operating segments are reported in a manner consistent with the internal reporting
provided to the chief operating decision-maker. The chief operating decision-maker, who is
responsible for allocating resources and assessing performance of the operating segments,
has been identified as the Chief Executive Officer who makes strategic decisions.
There are two operating segments at balance date:
1. Commercial: The sales, marketing, laboratory and support operations to run the
commercial businesses worldwide
2. Research: The research and development of diagnostic and prognostic products for
human cancer.
The reportable operating segment Commercial derives its revenue primarily from sales
of Cxbladder detection tests and the reportable operating segment Research derives its
revenue primarily from grant income. The Chief Executive Officer assesses the performance
of the operating segments based on net (loss) for the period.
Segment income, expenses and profitability are presented on a gross basis excluding inter-
segment eliminations to best represent the performance of each segment operating as
independent business units. The segment information provided to the Chief Executive
Officer for the reportable segment described above, for the period ended 30 September
2018, is shown below.
Unaudited 6 Months
to 30 September 2018
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total
External
Income
($000)
Income
Operating Revenue - External 2,033 - - 2,033
- Internal 76 - (76) -
Other Income 41 577 (176) 442
Interest Income 2 167 - 169
Foreign Exchange Gain - (4) (1) (5)
Total Income 2,152 740 (253) 2,639
Expenses
Expenses 7,348 4,068 (253) 11,163
Depreciation & Amortisation 66 129 - 195
Total Operating Expenses 7,414 4,197 (253) 11,358
Loss Before Tax (5,262) (3,457) - (8,719)
Net Cash Flow to Operating Activities (5,506) (3,106) - (8,612)
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2018
NOTES TO THE FINANCIAL STATEMENTS
Audited 12 Months
31 March 2018
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total
External
Income
($000)
Income
Operating Revenue - External 3,400 - - 3,400
- Internal 154 - (154) -
Other Income 127 2,137 (1,022) 1,242
Interest Income 2 3,158 (2,929) 231
Foreign Exchange Gain - 129 - 129
Total Income 3,683 5,424 (4,105) 5,002
Expenses
Expenses 18,834 9,413 (4,105) 24,142
Depreciation & Amortisation 191 313 - 504
Total Operating Expenses 19,025 9,726 (4,105) 24,646
Loss Before Tax (15,342) (4,302) - (19,644)
Net Cash Flow to Operating Activities (14,072) (4,028) - (18,100)
Unaudited 6 Months
30 September 2017 (RESTATED)
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total
External
Income
($000)
Income
Operating Revenue - External 1,425 - - 1,425
- Internal 47 - (47) -
Other Income 94 745 (301) 538
Interest Income - 81 - 81
Foreign Exchange Gain - 8 - 8
Total Income 1,566 834 (348) 2,052
Expenses
Expenses 7,810 4,360 (348) 11,822
Depreciation & Amortisation 122 147 - 269
Total Operating Expenses 7,932 4,507 (348) 12,091
Loss Before Tax (6,366) (3,673) - (10,039)
Net Cash Flow to Operating Activities (6,362) (3,823) - (10,185)
Eliminations
These are the intercompany transactions between the subsidiaries and the Parent. These
are eliminated on consolidation of Group results.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2018
NOTES TO THE FINANCIAL STATEMENTS
PACIFIC EDGE LIMITED INTERIM REPORT 2018
27 26
PACIFIC EDGE LIMITED INTERIM REPORT 2018

Segment Assets and Liabilities Information:
As at 30 September 2018
Commercial
($000)
Research
($000)
Total
($000)
Total Assets 2,493 11,310 13,803
Total Liabilities 2,100 809 2,909

As at 31 March 2018
Commercial
($000)
Research
($000)
Total
($000)
Total Assets 1,977 17,688 19,665
Total Liabilities 1,917 1,108 3,025
As at 30 September 2017
(RESTATED)
Commercial
($000)
Research
($000)
Total
($000)
Total Assets 2,070 5,863 7,933
Total Liabilities 1,570 1,142 2,712
Sales between segments are carried out at arm’s length. Post adoption of NZ IFRS 15,
the revenue from external parties reported to the Chief Executive Officer is measured in a
manner consistent with that in the Statement of Comprehensive Income.
Total Laboratory Throughput:
Commercial
(#tests)
Research
(#tests)
Total
(#tests)
Six months to 30 September 2018 6,078 1,319 7,397
Twelve months to 31 March 2018 11,866 2,582 14,448
Six months to 30 September 2017 5,439 1,680 7,119
Laboratory Throughput is a key metric for the Group: Laboratory Throughput provides
evidence of the increasing usage of Cxbladder products globally and the rates of adoption
between different customer segments. Total laboratory throughput includes billable/
commercial tests, which are invoiced to customers (including CMS tests), and tests which
are not considered to be billable as these tests relate to user programs or other non-
chargeable activities.
Billable/commercial test numbers are also a key metric for the Group: the tests are those
for which the Company is actively seeking reimbursement and cash receipts. Given the
time lag in the US between processing a Cxbladder test and receiving the associated cash
receipts, reported revenue based on the application of our accounting policy and billable
tests do not correlate in the same time period with one another. Billable test numbers also
include tests for CMS patients, which are all invoiced to CMS but for which revenue is not
being recognised.
Note that the Commercial and Research split shown above is reflective of the Billable/
Non-Billable split of laboratory throughput. Therefore the total of the Commercial tests
equals the total of the billable tests and all Research tests shown above are non-billable.
Non-billable tests may however be commercial in nature (ie. will lead to a commercial
relationship).
Additions to non-current assets for the period include:
Commercial
($000)
Research
($000)
Total
($000)
Property, Plant & Equipment 80 25 105
Intangible Assets - 71 71
Total Additions to Non Current Assets 80 96 176
The amounts provided to the Chief Executive Officer with respect to total assets and total
liabilities are measured in a manner consistent with that of the financial statements. These
assets and liabilities are allocated based on the operation of the segment and the physical
location of the asset.
There are no unallocated assets or liabilities.
8. SHARE CAPITAL
Sept 2018
6 Months
Shares (000)
Unaudited
Sept 2018
6 Months
($000)
Unaudited
Sept 2017
6 Months
($000)
Audited
March 2018
12 Months
($000)
Opening Balance 466,322 131,824 111,596 111,596
Issue of Ordinary Shares - Rights Issue
and Direct Offers
8,195 2,623 - 21,318
Issue of Ordinary Shares - Exercise of
Share Options
- - 112 112
Issue of Ordinary Shares - Employee
Remuneration
275 88 80 96
Less: Issue Expenses - (23) - (1,298)
Movement 8,470 2,688 192 20,228
Closing Balance 474,792 134,512 111,788 131,824
There are 474,792,378 (March 2018: 466,321,801 and September 2017: 399,704,401) Ordinary
Shares on issue.
All fully paid shares in the Company have equal voting rights and equal rights to dividends.
All Ordinary Shares are fully paid and have no par value.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2018
NOTES TO THE FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2018
NOTES TO THE FINANCIAL STATEMENTS
PACIFIC EDGE LIMITED INTERIM REPORT 2018
29 28
PACIFIC EDGE LIMITED INTERIM REPORT 2018

9. RECONCILIATION OF CASH USED FROM OPERATING ACTIVITIES WITH
OPERATING NET LOSS
Sept 2018
6 Months
($000)
Sept 2017
6 Months
($000)
RESTATED
March 2018
12 Months
($000)
Net Loss for the Period (8,719) (10,039) (19,644)
Add Non Cash Items:
Depreciation 116 179 316
Loss on Disposal of Property, Plant and Equipment - - 10
Amortisation 79 90 188
Employee Share Options 284 141 1,184
Employee Bonuses Paid in Shares in Lieu of Cash 88 80 96
Effect of Exchange Rates on Net Cash 6 (9) (131)
Total Non Cash Items 573 481 1,663
Add Movements in Other Working Capital items:
(Increase) in Receivables and Other Assets (80) (292) (383)
(Increase)/Decrease in Inventory (94) (190) 72
(Decrease)/Increase in Payables and Accruals (292) (145) 192
Total Movement in Other Working Capital (466) (627) (119)
Net Cash Flows to Operating Activities (8,612) (10,185) (18,100)
10. CONTINGENT LIABILITIES
There were no known contingent liabilities at 30 September 2018 (March 2018: Nil and
September 2017: Nil). The Company and Group have not granted any securities in respect
of liabilities payable by any other party whatsoever.
11. CAPITAL COMMITMENTS
There are no capital commitments at 30 September 2018 (March 2018: Nil and September
2017: Nil).
12. SUBSEQUENT EVENTS
New Capital
The Company announced on the 29th of November 2018 that it is completing a private
placement to new and existing shareholders. This private placement is expected to result
in additional capital for the Company of up to $7m. The Company also announced on the
same day a Share Purchase Plan to raise up to $5m of capital from existing shareholders.
The Share Purchase Plan has not been underwritten and is expected to open in December
2018 and close in January 2019.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2018
NOTES TO THE FINANCIAL STATEMENTS
National Pricing for CMS
On the 12th of October 2018, the Company announced that the preliminary national CMS
reimbursement rate of US$760 per Cxbladder test had been publicly notified. This pricing
was finalised during November 2018 and takes effect from 1 January 2019. Obtaining the
pricing is the second of three steps to enable the Company to be reimbursed by CMS for
Cxbladder tests performed for CMS patients. The third and final step is the inclusion of
Cxbladder in the Local Coverage Determination (LCD) which the Company continues to
work towards achieving.
13. GOING CONCERN
The Interim Financial Statements have been prepared on the going concern basis which
assumes that the Company will have sufficient cash to pay its debts as they fall due for a
minimum of 12 months from the signing of the Interim Financial Statements.
As at 30 September 2018, the Company had $10.060m of cash and cash equivalents on
hand (2017: $3.997m) and net assets of $10.894m (2017: $5.221m). Cash receipts totalling
$2.939m were received in the six month period to 30 September 2018 (2017: $1.962m) along
with additional capital of $2.623m (2017: $94k). Net cash out flows from operating activities
for the six month period to 30 September 2018 were $8.612m (2017: $10.185m).
While the Company continues to incur operating losses, the Company remains solvent and
continues to pay its debts as they fall due. The Company continues to progress commercial
negotiations with targeted large scale health organisations in the USA and whilst these
negotiations are taking longer than expected to complete, the Company continues to
make good progress with these negotiations. The new contracts that will result from these
commercial negotiations will have a significant positive impact on the Company’s financial
position once they are concluded.
The Company has prepared cash flow forecasts which indicates that if these commercial
negotiations continue to be delayed, the Company may not have sufficient cash to meet its
minimum expenditure commitments and support its current levels of activity. The Company
may therefore need to raise additional funds to continue as a going concern.
To address the future additional funding requirements of the Company, the Directors have:
- Entered into discussions to secure additional equity funding from current or new
shareholders,
- Continued to monitor the Company’s ongoing working capital requirements and
minimum expenditure commitments, and
- Continued to focus on maintaining an appropriate level of expenditure in line with the
Company’s available cash resources.
The Directors are confident that they will be able to obtain additional equity funding to
enable the Company to meet its minimum expenditure requirements and support its planned
level of expenditure. However, in the event that the Company is not able to successfully
complete the fundraising, a material uncertainty may exist which may cast significant doubt
on the Company’s ability to continue as a going concern with the current capital and cost
structures.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2018
NOTES TO THE FINANCIAL STATEMENTS
PACIFIC EDGE LIMITED INTERIM REPORT 2018
31 30
PACIFIC EDGE LIMITED INTERIM REPORT 2018

COMPANY DIRECTORY
As at 30 September 2018
Issued Capital
474,792,378 Ordinary Shares
Registered Office
Anderson Lloyd
Level 10, Otago House
Cnr Moray Place and Princes Street
Dunedin
Directors
C. Gallaher – Chairman
D. Darling
D. Levison
A. Masfen
S. Park
(appointed 6 December 2018)
B. Williams
Chief Executive Officer
David Darling
Nature of Business
Research, develop and commercialise new
diagnostic and prognostic tools for the early
detection and management of cancers.
Auditors
PricewaterhouseCoopers
Dunedin
Bankers
Bank of New Zealand
Dunedin
ANZ
Dunedin
Solicitors
Anderson Lloyd
Level 10, Otago House
Cnr Moray Place and Princes Street
Dunedin
Securities Registrar
Link Market Services Limited
138 Tancred St
Ashburton
Company Number
1119032
Date of Incorporation
27th February 2001

PACIFIC EDGE COMMUNICATIONS

Websites
www.pacificedgedx.com
www.cxbladder.com
www.bladdercancer.me
Facebook
www.facebook.com/PacificEdgeLtd
www.facebook.com/Cxbladder
Twitter
@PacificEdgeLtd
@Cxbladder
LinkedIn
www.linkedin.com/company/pacific-edge-ltd
87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 479 5800 F +64 3 479 5801